Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Would you offer adjuvant radiation therapy for a completely resected, node positive mucoepidermoid carcinoma of the lung?
Related Questions
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
For NSCLC patients treated with neoadjuvant chemoimmunotherapy and surgery with ypN2 disease, what factors would cause you to recommend PORT?
What dose contraints do use for the pulmonary artery and vein when treating with a lung lesion with SBRT?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
Would you give lung SBRT to a patient with bullous pemphigoid on the chest and torso?
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Do more fractionated regimens reduce severe toxicity over SBRT in patients with ILD and early-stage NSCLC?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
Do you restrict the dose rate during treatment delivery to a pacemaker in addition to limiting the Dmax?
